|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$22,000
|
N/A
|
National Institutes of Health
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
$135,414
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
$38,405
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
$1,251,228
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain Tumors
|
5R01CA155769-07
|
$410,877
|
|
BADIE, BEHNAM
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Dietary fats, mitochondrial function and muscle health in cancer patients
|
1R21CA209566-01A1
|
$199,655
|
|
BELURY, MARTHA
|
OHIO STATE UNIVERSITY
|
|
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma
|
5R01CA210250-02
|
$390,134
|
|
BHALLA, KAPIL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Discovery, Biology and Risk of Inherited Variants in Glioma
|
1R01CA217105-01A1
|
$1,043,807
|
|
BONDY, MELISSA
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Structure, Function and Regulation of Eukaryotic DNA Replication Initiator Complexes
|
5R01CA030490-37
|
$610,461
|
|
BOTCHAN, MICHAEL
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
Oncogenic Met Signaling in Urologic Malignancies
|
ZIA BC 011124
|
$396,445
|
$7,929
|
Bottaro, Donald
|
CCR (NCI)
|
|
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer
|
5P50CA196516-03
|
$2,300,000
|
$322,000
|
BRUGAROLAS, JAMES
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Stable Water Isotope Labeling for Imaging of Rapidly Proliferating Cells
|
ZIA BC 011777
|
$32,855
|
$657
|
Buxbaum, Nataliya
|
CCR (NCI)
|
|
Dynamic Optical Imaging Biomarkers of Tumor Response to Therapy
|
5R01CA187595-04
|
$526,893
|
|
CARP, STEFAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Novel tumorigenic mechanisms of the LKB1 tumor suppressor
|
5R01CA196912-03
|
$370,575
|
|
CASTRILLON, DIEGO
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
The role of PLAG1 in Wilms tumor formation
|
5K08CA207849-02
|
$156,645
|
$156,645
|
CHEN, KENNETH
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Early detection of pancreatic cancer in diabetics
|
5R01CA180949-05
|
$584,528
|
|
CHEN, RU
|
UNIVERSITY OF WASHINGTON
|
|
Inducible systems for studying liver tumor mainenance in vivo
|
5R03CA208311-02
|
$79,250
|
|
CHEN, XIN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The molecular mechanisms of metabolism reprogramming in mutant Kras/Ink4a-driven pancreatic ductal adenocarcinoma
|
5R01CA207031-02
|
$366,000
|
|
CHIAO, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
In Vivo Oncogene-Induced Tumorigenesis and Escape
|
5R01CA098371-12
|
$382,375
|
|
CHODOSH, LEWIS
|
UNIVERSITY OF PENNSYLVANIA
|
|
Evaluating How Tobacco Control Policies are Shaping the Nicotine Delivery Market
|
5P01CA200512-03
|
$2,893,402
|
|
CUMMINGS, KENNETH
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Defining the contribution of ATR to MC1R-enhanced DNA repair in melanocytes
|
5R01CA131075-08
|
$338,625
|
|
D'ORAZIO, JOHN
|
UNIVERSITY OF KENTUCKY
|
|
Obesity Increases Breast Cancer Penetrance in BRCA Mutation Carriers: A Role for Local and Systemic Factors
|
5R01CA215797-02
|
$555,691
|
|
DANNENBERG, ANDREW
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Childrens Oncology Group Statistics and Data Center
|
5U10CA180899-05
|
$7,738,106
|
$773,811
|
DEVIDAS, MEENAKSHI
|
UNIVERSITY OF FLORIDA
|
|
Targeting the GFI1-LSD1 Axis in T-Cell Acute Lymphoblastic Leukemia
|
5R01CA201235-02
|
$348,273
|
|
ENGEL, MICHAEL
|
UNIVERSITY OF UTAH
|
|
Epigenetic Regulation by CHD7 in Colon Cancer
|
5R21CA215108-02
|
$174,000
|
|
ESTECIO, MARCOS
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Targeting lung and breast cancer cell oxidative metabolism with D-penicillamine and disulfiram
|
5F30CA213817-02
|
$34,592
|
|
FALLS, KELLY
|
UNIVERSITY OF IOWA
|
|
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
|
5R01CA206517-03
|
$499,177
|
|
FERRIS, ROBERT
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
|
5R01CA196947-03
|
$349,968
|
|
FIGUEIREDO, MARXA
|
PURDUE UNIVERSITY
|
|
Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance
|
5R01CA214880-02
|
$237,158
|
|
FLYNN, RACHEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Identifying causal variants and genes underlying breast cancer risk loci
|
5R01CA204954-03
|
$606,904
|
|
FREEDMAN, MATTHEW
|
DANA-FARBER CANCER INST
|
|
Outcomes associated with significant incidental findings in lung cancer screening
|
5R01CA204222-02
|
$317,576
|
|
GAREEN, ILANA
|
BROWN UNIVERSITY
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-07
|
$413,844
|
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Molecular and Translational Oncology Research
|
5T32CA203702-02
|
$282,148
|
|
GIANNAKAKOU, PARASKEVI
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Imaging Habitats in Sarcoma
|
5R01CA187532-04
|
$448,046
|
|
GILLIES, ROBERT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Targeting Kinesin Family Member 15 for the Treatment of Cancer
|
5R01CA214545-02
|
$623,043
|
|
GODWIN, ANDREW
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
|
ZIA BC 005598
|
$584,807
|
$5,848
|
Gottesman, Michael
|
CCR (NCI)
|
|
Mechanisms of non-classical multidrug resistance in cancer
|
ZIA BC 010830
|
$804,110
|
$8,041
|
Gottesman, Michael
|
CCR (NCI)
|
|
Nuclear Factor I/B Action in Castrate Resistant Prostate Cancer
|
5R00CA197315-05
|
$170,316
|
|
GRABOWSKA, MAGDALENA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Carcinogenesis Training Program
|
5T32CA009560-32
|
$374,954
|
|
GREEN, KATHLEEN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
5R01CA211328-02
|
$404,888
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of novel anti-leukemia agents targeting the menin-MLL interaction
|
5R01CA160467-07
|
$372,258
|
|
GREMBECKA, JOLANTA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer
|
5R01CA206493-03
|
$439,200
|
|
GRIFFIN, PATRICK
|
SCRIPPS FLORIDA
|
|
Hypermutation and malignant progression in an expanded cohort of TMZ treated LGG patients from different molecular subgroups
|
5F32CA206252-03
|
$26,585
|
|
GRIMMER, MATTHEW
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Liver Cancer Risk with rAAV Gene Therapy
|
5R01CA190144-04
|
$586,035
|
|
GROMPE, MARKUS
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Enabling a new route for the creation of short, diverse peptide libraries through breaking the degeneracy of the genetic code
|
5R03CA216116-02
|
$72,735
|
|
HARTMAN, MATTHEW
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)
|
5R01CA186566-04
|
$620,205
|
|
HASSAN, MANAL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
|
5R01CA205150-03
|
$605,252
|
|
HEYMACH, JOHN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients
|
5R01CA207183-02
|
$377,127
|
|
JATOI, AMINAH
|
MAYO CLINIC ROCHESTER
|
|
Retrospective NCI Phantom-Monte Carlo Dosimetry for Late Effects in Wilms Tumor
|
5R01CA219013-02
|
$586,471
|
$586,471
|
KALAPURAKAL, JOHN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
Total relevant funding to Wilm's Tumor for this search: $6,097,335
|